Developing a new treatment for Alzheimer's disease by targeting stress response mechanisms
Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
This study is working on a new treatment for Alzheimer's disease that aims to calm down a part of the brain that gets too active and can worsen the condition, hoping to offer a safe and effective option for managing the disease over time.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stress Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11077619 on NIH RePORTER |
What this research studies
This research focuses on creating a novel treatment for Alzheimer's disease by addressing the overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, which is linked to the progression of the disease. The approach involves developing a first-in-class therapeutic candidate that aims to normalize the hyperactivity of the HPA axis, which can have detrimental effects on brain function. By exploring new compounds that can effectively modulate this stress response, the research seeks to provide a long-term management solution for Alzheimer's and related conditions. Patients may benefit from a treatment that is both effective and tolerable for long-term use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing symptoms related to excessive HPA axis activation.
Not a fit: Patients with early-stage Alzheimer's disease or those who do not exhibit symptoms related to HPA axis dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves the management of Alzheimer's disease and enhances the quality of life for patients.
How similar studies have performed: While there have been studies on glucocorticoid receptor antagonists and CRF1 antagonists, this approach is considered novel as it aims to develop a more effective and tolerable treatment specifically targeting HPA hyperactivity in Alzheimer's disease.
Where this research is happening
San Diego, United States
- Stress Therapeutics, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Lloyd, Linda S — Stress Therapeutics, INC.
- Study coordinator: Lloyd, Linda S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.